Skip to main content
. Author manuscript; available in PMC: 2011 Apr 4.
Published in final edited form as: J Immunol. 2010 Jan 8;184(4):1858–1866. doi: 10.4049/jimmunol.0903210

FIGURE 2.

FIGURE 2

IL-12 suppresses VEGFR3 on tumor vessels. B16 or B16/IL-12 cells (2 × 105) were injected i.m. into (A) WT or (B) IL-12Rβ2−/− mice and grown to a mean thigh diameter of 10–13 mm. Representative images of whole mount preparations of B16 (top rows) and B16/IL-12 (bottom rows) are shown stained with biotinylated anti-VEGFR3 and PE-streptavidin (pseudo-colored red) and FITC-conjugated anti-CD31 (pseudo-colored green). Scale bar, 50 μm.